No Photo Available

Last Update

2016-08-02T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Renier Brentjens?

Dr. Renier J. Brentjens

Director of Cellular Therapeutics

MSKCC

HQ Phone: (212) 639-2000

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

MSKCC

1275 York Avenue

New York, New York 10065

United States

Company Description

Memorial Sloan Kettering Cancer Center is the world's oldest and largest private cancer center, having devoted more than 130 years to exceptional patient care, innovative research, and outstanding educational programs. Today, it is one of 45 National Canc ... more

Find other employees at this company (14,373)

Background Information

Employment History

Juno Therapeutics, Inc.

Affiliations

Member of Laboratory
The Chemotherapy Foundation

Member of Laboratory
Sadelain

Education

MD

SUNY Buffalo

Web References (170 Total References)


"I call it a Frankenstein-like molecule," ...

www.focr.org [cached]

"I call it a Frankenstein-like molecule," said Dr. Renier J. Brentjens, the director of cellular therapeutics at Memorial Sloan Kettering Cancer Center.


Faculty | TAT Congress

tatcongress.org [cached]

Renier J. Brentjens Director, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center, New York, NY, USA


Juno Therapeutics |

junotherapeutics.com [cached]

DR. RENIER BRENTJENS

...
DR. RENIER BRENTJENS
Scientific co-founder
Dr Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale-New Haven Hospital, and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC). Currently, Dr Brentjens is an associate member on the faculty at MSKCC and an attending physician on the Leukemia Service. As a medical oncology fellow at MSKCC, Dr Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr Brentjens became the principle investigator of his own laboratory. As a PI, Dr Brentjens successfully translated these studies to the clinical setting, treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of "armored CAR T cells" currently being translated to the clinical setting as second generation CAR modified T cell clinical trials. Additionally, work in the Brentjens' lab has expanded this CAR technology to target additional tumor antigens.
More Info on Dr. Brentjens
...
Michel Sadelain and Renier J. Brentjens of Memorial Sloan Kettering Cancer Center, for winning the esteemed New York Intellectual Property Law Association (NYIPLA) "Inventor of the Year" award.
...
Sadelain and Brentjens were recognized for their extensive work in the design of chimeric antigen receptors (CARs).


CHIMERIC ANTIGEN RECEPTORS (CARs) | Juno Therapeutics - Part 2

junotherapeutics.com [cached]

DR. RENIER BRENTJENS

...
DR. RENIER BRENTJENS
Scientific co-founder
Dr Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale-New Haven Hospital, and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC). Currently, Dr Brentjens is an associate member on the faculty at MSKCC and an attending physician on the Leukemia Service. As a medical oncology fellow at MSKCC, Dr Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr Brentjens became the principle investigator of his own laboratory. As a PI, Dr Brentjens successfully translated these studies to the clinical setting, treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of "armored CAR T cells" currently being translated to the clinical setting as second generation CAR modified T cell clinical trials. Additionally, work in the Brentjens' lab has expanded this CAR technology to target additional tumor antigens.
More Info on Dr. Brentjens
...
Michel Sadelain and Renier J. Brentjens of Memorial Sloan Kettering Cancer Center, for winning the esteemed New York Intellectual Property Law Association (NYIPLA) "Inventor of the Year" award.
...
Sadelain and Brentjens were recognized for their extensive work in the design of chimeric antigen receptors (CARs).


Pictured: Isabelle Rivière, Michel Sadelain ...

www.mskcc.org [cached]

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens

...
(From left) Investigators Isabelle Rivière, Michel Sadelain, and Renier Brentjens are founders of Juno Therapeutics.
...
Dr. Sadelain and two other Memorial Sloan Kettering researchers - Renier Brentjens, Director of Cellular Therapeutics, and Isabelle Rivière, Director of the Cell Therapy and Cell Engineering Facility - are playing a critical role in the formation of Juno and are founding scientists of the company. (All three researchers will continue in their roles at Memorial Sloan Kettering.)
...
Pictured: Renier J. Brentjens
...
Renier J. Brentjens - Researcher Profile

Similar Profiles

Other People with this Name

Other people with the name Brentjens

Jan Brentjens
Saint Peter's Prep

Cas Brentjens
Infor Inc

Bart Brentjens
The Team

Renier Brentjens
Castle Connolly Medical Ltd.

Brend Brentjens
Lemon Companies

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory